Obesity, haemostasis and the fibrinolytic system

Obesity Reviews

Volumn 3, Issue 2, 2002, Pages 85-101

  Mertens, I ^a   Van Gaal, L F ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Fibrinolysis; Haemostasis; Obesity

Indexed keywords

BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; FIBRINOGEN; INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; VON WILLEBRAND FACTOR;

ADIPOCYTE; CARDIOVASCULAR RISK; CORRELATION ANALYSIS; FIBRINOLYSIS; HEMOSTASIS; HUMAN; INSULIN RESISTANCE; OBESITY; PATHOGENESIS; REVIEW; RISK FACTOR; WEIGHT REDUCTION;

BLOOD COAGULATION FACTORS; BODY CONSTITUTION; CARDIOVASCULAR DISEASES; FACTOR VII; FACTOR VIII; FIBRINOGEN; FIBRINOLYSIS; HEMOSTASIS; HUMANS; INSULIN RESISTANCE; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; VON WILLEBRAND FACTOR; WEIGHT LOSS;

EID: 0036322988     PISSN: 14677881     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1467-789X.2002.00056.x     Document Type: Review

References (155)

1. Effects of lipids and lipoproteins on thrombosis and rheology
2. Polymorphisms of coagulation/fibrinolysis genes: Gene environment interactions and vascular risk
3. Haemostatic parameters and vascular risk
4. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men
5. Body weight and mortality among women
6. American Heart Association call to action: Obesity as a major risk factor for coronary heart disease
7. Interrelations between carbohydrates, lipids, and the hemostatic system in relation to the risk of thrombotic and cardiovascular disease
8. Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature
9. Fibrin(ogen) and diabetes mellitus: Don't forget fibrinolysis
10. Fibrinogen as a risk factor for stroke and myocardial infarction
11. Hemostatic function and cardiovascular death: Early results of a prospective study
12. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study
13. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study
14. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men
15. Update on fibrinogen as a cardiovascular risk factor
16. Influence of fibrinogen on cardiovascular disease
17. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
18. Blood coagulation and fibrinolysis in obese NIDDM patients
19. Associations of fibrinogen and coagulation factors VII and VIII with cardiovascular risk factors in the elderly. The Cardiovascular Health Study
20. Plasma fibrinogen and ischemic heart disease risk factors
21. Determinants of population changes in fibrinogen and factor VII over 6 years. The Atherosclerosis Risk in Communities (ARIC) Study
22. Sex differences in coagulation and fibrinolysis in subjects with coronary artery disease
23. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population. I. Baseline data on the relation to age, gender, body weight, smoking, alcohol, pill-using, and menopause
24. Lifestyle and hemostatic risk factors for ischemic heart disease. The Caerphilly Study
25. Association of sex hormones and adiposity with plasma levels of fibrinogen and PAI-1 in postmenopausal women
26. Fibrinogen genotype and risk of peripheral atherosclerosis
27. β fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM study
28. Blood viscosity in human obesity: Relation to glucose tolerance and insulin status
29. Haemorheological changes in obese adolescents after short-term diet
30. Evaluation of cardiovascular risk factors in overweight and obese subjects
31. Hemostatic function in young subjects with central obesity: Relationship with left ventricular function
32. Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults
33. Fibrinogen, other putative markers of inflammation, and weight gain in middle-aged adults - The ARIC Study
34. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1
35. Coagulation, fibrinolysis and haemorheology in pre-menopausal obese women with different body fat distribution
36. Hemostatic and metabolic variables in women with polycystic ovary syndrome
37. Fibrinogen in obesity before and after weight reduction
38. Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men
39. Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris
40. Association of proinsulin-like molecules with lipids and fibrinogen in non-diabetic subjects - Evidence against a modulating role for insulin
41. Proinsulin, intact insulin, and fibrinolytic variables and fibrinogen in healthy subjects. A population study
42. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance
43. Hyperinsulinemia, hyperglycemia, and impaired hemostasis. The Framingham Offspring Study
44. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2
45. Clustering of procoagulation, inflammation and fibrinolysis variables with metabolic factors in insulin resistance syndrome
46. Reduction in factor VII, fibrinogen and plasminogen activator inhibitor-1 activity after surgical treatment of morbid obesity
47. Sustained improvement in blood lipids, coagulation, and fibrinolysis after major weight loss in obese subjects
48. Effect of weight reduction on blood viscosity parameters in obese women
49. Effect of a short-term very low calorie diet on plasma lipids, fibrinogen and factor VII in obese subjects
50. Plasminogen activator inhibitor-1, tissue-type plasminogen activator, and fibrinogen. Effect of dieting with or without exercise in overweight postmenopausal women
51. Fibrinolytic activity and clotting factors in ischaemic heart disease in women
52. Prospective study of hemostatic factors and incidence of coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study
53. The PLAT study: Hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results
54. Population correlates of coagulation factor VII. Importance of age, sex, and menopausal status as determinants of activated factor VII
55. Circulating levels of factor VII, fibrinogen, and von Willebrand factor and features of insulin resistance in first-degree relatives of patients with NIDDM
56. Effect of weight loss on coagulation factors VII and X
57. Fat consumption and factor VII coagulant activity in middle-aged men
58. Factor VII coagulant activity in relation to serum lipoproteins and dietary fat in middle-aged men
59. Effect of diet composition on coagulation pathways
60. Influence of dietary fat type on arterial thrombosis tendency
61. Liver steatosis and its relation to plasma haemostatic factors in apparently healthy men - Role of the metabolic syndrome
62. Lower androgenicity is associated with higher plasma levels of prothrombotic factors irrespective of age, obesity, body fat distribution, and related metabolic parameters sin men
63. Increase in both prothrombotic and anti-thrombotic factors in obese premenopausal women: Relationship with body fat distribution
64. Plasma factor VII and its relation to adipose tissue fatty acids and other atherogenic risk factors in healthy men
65. Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome
66. Factor VII gene polymorphisms, factor VII:c levels and features of insulin resistance in non-insulin-dependent diabetes mellitus
67. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study
68. Haemostatic function in myocardial infarction
69. Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis
70. Von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 year follow-up of survivors of acute myocardial infarction
71. Plasma levels of tissue plasminogen activator/plasminogen inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study
72. Von Willebrand factor, c-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects. The Hoorn Study
73. Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study
74. Von Willebrand factor, the endothelium and obesity
75. The effects of saturated and n-6 polyunsaturated fat on postprandial lipemia and hemostatic activity
76. Insulin sensitivity and haemostatic factors in men at high and low cardiovascular risk
77. Von Willebrand factor and fibrinolytic variables are differently affected in the insulin resistance syndrome
78. Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects
79. Hypofibrinolyis and insulin-resistance
80. Mechanisms of physiological fibrinolysis
81. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction
82. Von Willebrand factor in plasma: A novel risk factor for recurrent myocardial infarction and death
83. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up
84. Endogenous tissue-type plasminogen activator and risk of myocardial infarction
85. Prospective study of endogenous tissue plasminogen activator and risk of stroke
86. Fibrinolysis and atherosclerosis
87. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women. Evidence for the fibrinolytic system as an independent primary risk factor
88. Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly Study
89. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke
90. Daytime fluctuations in blood tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (PAI-1)
91. Plasminogen activator inhibitor-1 (PAI-1) antigen plasma levels in subjects attending a metabolic ward: Relation to polymorphisms of PAI-1 and angiotensin converting enzyme (ACE) genes
92. Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10.500 male participants in a prospective study of myocardial infarction
93. Enhanced expression of PAI-1 in visceral fat: Possible contributor to vascular disease in obesity
94. PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis. Relation to environmental and genetic determinants
95. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study
96. Plasminogen activator inhibitor in plasma is related to testosterone in men
97. Fasting blood coagulation and fibrinolysis of young adults unchanged by reduction in dietary fat content
98. Favorable long-term effect of a low-fat/high-fiber diet on human blood coagulation and fibrinolysis
99. PAI-1 concentrations in first-degree relatives of patients with non-insulin-dependent diabetes: Metabolic and genetic associations
100. The 4G/5G polymorphism in the plasminogen acti-vator inhibitor-1 gene is not associated with myocardial infarction
101. Plasminogen activator inhibitor-1 promotor 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography
102. The 4G/5G polymorphism of PAI-1 promotor gene and the risk of myocardial infarction: A meta-analysis
103. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men
104. Correlation between fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects
105. Fat distribution and plasminogen activator inhibitor activity in non-diabetic obese women
106. Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women
107. Visceral fat accumulation is an important determinant of PAI-1 levels in young, non-obese men and women. Modulation by cross-sex hormone administration
108. Fat distribution and hemostatic measures in obese children
109. Relationship between visceral fat and PAI-1 in overweight men and women before and after weight loss
110. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor- α, and transforming growth factor-β
111. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo
112. Production of plasminogen activator inhibitor 1 by human adipose tissue. Possible link between visceral fat accumulation and vascular disease
113. Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals
114. Expression of plasminogen activator inhibitor-1 in human adipose tissue: Role for TNF-α?
115. Effect of tumor necrosis factor alpha and transforming growth factor beta 1 on plasminogen activator inhibitor-1 secretion from subcutaneous and omental human fat cells in suspension culture
116. PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level
117. Regional variation in plasminogen activator inhibitor-1 expression in adipose tissue from obese individuals
118. 1, and BMI are closely associated in human adipose tissue during morbid obesity
119. Role of cytokines in the regulation of plasminogen activator inhibitor-1 expression and secretion in newly differentiated subcutaneous human adipocytes
120. Hormonal control of plasminogen activator inhibitor-1 gene expression and production in human adipose tissue: Stimulation by glucocorticoids and inhibition by catecholamines
121. Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue
122. Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance
123. Subcutaneous adipose tissue expression of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic and type 2 diabetic subjects
124. Plasma leptin levels are associated with abnormal fibrinolysis in men and postmenopausal women
125. Plasma plasminogen activator inhibitor-1 is associated with plasma leptin irrespective of body mass index, body fat mass, and plasma insulin and metabolic parameters in premenopausal women
126. Insulin sensitivity is not an independent determinant of plasma plasminogen activator inhibitor-1 activity
127. Association of blood pressure with fibrinolytic potential in the Framingham offspring population
128. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and lean and obese normal subjects
129. Low-density lipoprotein particle size is inversely related to plasminogen activator inhibitor-1 levels. The Insulin Resistance Atherosclerosis Study
130. Small, dense LDL particle concentration correlates with plasminogen activator inhibitor type-1 activity
131. The effect of body build, diet and endocrine factors on the extrinsic fibrinolytic system in healthy young women
132. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance
133. Determinants of plasminogen activator inhibitor-1 activity in survivors of myocardial infarction
134. Comparison of plasminogen activator inhibitor-1 concentration in insulin-resistant versus insulin-sensitive healthy women
135. Insulin sensitivity and hemostatic factors in clinically healthy 58-year-old men
136. Plasminogen activtor inhibitor 1: Biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes
137. Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease
138. Attenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients
139. Glucose and insulin independently reduce the fibrinolytical potential of human vascular smooth muscle cells in culture
140. Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARγ in endothelial function
141. Differential regulation by troglitazone of plasminogen activator inhibitor type 1 in human hepatic and vascular cells
142. Genotype-specific transcriptional regulation of PAI-1 expression by hypertriglyceridemic VLDL and Lp(a) in cultured human endothelial cells
143. Hypertriglyceridemia and regulation of fibrinolytic activity
144. Stimulating effect of oxidized low density lipoproteins on plasminogen activator-1 synthesis by endothelial cells
145. The acute effect of insulin on tissue plasminogen activator and plasminogen activator inhibitor in man
146. Short-term infusion of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen activator inhibitor-1 concentrations in man
147. Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects
148. Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with polycystic ovary syndrome
149. Normal plasminogen activator inhibitor levels at long-term follow-up after jejuno-ileal bypass surgery in morbidly obese individuals
150. Beneficial effect of a moderately energy restricted diet on fibrinolytic factors in non-obese men
151. Amelioration of the inhibition of fibrinolysis in elderly, obese subjects by moderate energy intake restriction
152. Improved fibrinolysis by intense lifestyle intervention. A randomized trial in subjects with impaired glucose tolerance
153. Impact of adipose tissue on plasma plasminogen activator inhibitor-1 in dieting obese women
154. Subcutaneous adipose tissue expression of plasminogen activator inhibitor-1 gene during very low calorie diet in obese subjects